Arena Pharmaceuticals announced that Belviq (lorcaserin HCl) tablets will be available in pharmacies beginning June 11, 2013. Belviq tablets will be marketed and distributed by Eisai Inc. The Drug Enforcement Administration (DEA) has classified Belviq as a Schedule IV substance.

RELATED: Metabolic Disorders Resource Center

Belviq was approved in June 2012 as adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of >30kg/m2 (obese), or >27kg/m2 (overweight) in the presence of at least one weight related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes).

Belviq is a serotonin 2C receptor agonist that is believed to decrease food consumption and promote satiety by selectively activating 5-HT2C receptors on anorexigenic pro-opiomelanocortin neurons located in the hypothalamus.

Belviq will be available as 10mg film-coated tablets in 60-count bottles.

For more information call (888) 274-2378 or visit